Skip to content

In the BioHarmony Drug Report Database

Lidocaine

Dentipatch, Lidoderm, Xylocaine, Ztlido, Fortacin, Senstend (lidocaine) is a small molecule pharmaceutical. Lidocaine was first approved as Dentipatch on 1982-01-01. It is used to treat burns, cardiac arrhythmias, esophageal diseases, mouth diseases, and pain amongst others in the USA. It has been approved in Europe to treat physiological sexual dysfunction and premature ejaculation. The pharmaceutical is active against sodium channel protein type 5 subunit alpha. In addition, it is known to target sodium channel protein type 2 subunit alpha, sodium channel protein type 4 subunit alpha, sodium channel protein type 9 subunit alpha, and sodium channel protein type 10 subunit alpha. Lidocaine's patent is valid until 2031-05-10 (FDA).
Trade Name Fortacin, Senstend
Common Name Lidocaine
Indication burns, cardiac arrhythmias, esophageal diseases, mouth diseases, pain, paroxysmal tachycardia, physiological sexual dysfunction, premature ejaculation, ventricular fibrillation, ventricular premature complexes, ventricular tachycardia
Drug Class Local anesthetics
Lidocaine
Get full access now